Novartis acquires biotech Myricx Bio to strengthen its oncology pipeline in a $1,1 billion deal.
Myricx is working on a new "family" of antibody-drug conjugates, which have become an important part of cancer treatment.
Novartis Acquires New Breast Cancer Drug in $3 Billion Deal
Novartis strengthens its position in the breast cancer treatment sector with the acquisition of an experimental drug from the US group Synnovation Therapeutics.
Novartis acquires Avidity Biosciences for $12 billion: a major biotech acquisition to focus on RNA.
The Swiss multinational is focusing on RNA therapies for rare muscle diseases. This is the group's largest acquisition in over a decade.
Novartis acquires U.S. biotech company Tourmaline Bio for $1,4 billion, a 60% premium.
The Swiss pharmaceutical company is willing to pay $48 per share: its main attraction is the development of a promising treatment to reduce systemic inflammation, one of the main causes of cardiovascular disease.
Pharmaceuticals: from Gsk to Novartis, excellent results for companies in the EU but Trump's duties loom. What are the risks?
Pharmaceuticals is one of the best-performing sectors. Sanofi and GSK beat profit expectations, while Novartis and Recordati raised their forecasts. But Trump’s axe could force some companies to move…
Switzerland: For the super-rich, franc and houses are once again the refuge from Trump. Instead, companies go to produce in the USA
In the market turbulence triggered by Trump's trade war, investors are seeking refuge not only in gold, but also in the Swiss franc. The super-rich Americans are also moving their assets and families to the Swiss mountains
Ptc Therapeutics: $2,9 billion deal with Novartis for new experimental drug, stock price booms +20%
Ptc Therapeutics soars on the stock market with a +20% thanks to the exclusive agreement with Novartis for the PTC518 program against Huntington's disease. Agreement worth over 2,9 billion dollars. Agreement on profits In the United States
Novartis soars in the second quarter: growing sales and rising profits
The Swiss pharmaceutical company exceeds expectations with an excellent second quarter. Net sales up 11%, core operating profit up 43%. Strong momentum across all segments, with innovations and expanding pipeline. The company revises upward…
Novartis invests in Italy. 350 million for research and production of innovative drugs
The Swiss big pharma has announced investments in the country to strengthen the production lines, in particular at the Ivrea and Torre Annunziata sites. 100 hires are also expected
Novartis: spin-off and listing of Sandoz on the Stock Exchange to create a giant of generic drugs
Novartis has announced its intention to spin off its Sandoz subsidiary, which specializes in generic medicines, and to list it on the Zurich Stock Exchange and in the United States
Novartis buys optogenetics company for 1,5 billion
Swiss drugmaker continues its pharmaceutical buyouts - This time it's up to the British ocular gene therapy firm to speed up trials for the treatment of geographic atrophy, a leading cause of blindness
Enel GP-Novartis: agreement on 100% renewable energy
Enel Green Power to supply Novartis with 78 MW of renewable energy produced in the Tico wind farm - The pharmaceutical company will be able to avoid the immission of 96.400 tons of CO2 each year
Alibaba, booming debut on the Hong Kong Stock Exchange: +7%
Sparkling corporate deals in the past few hours - Tiffany, Novartis, Charles Schwab and Alibaba's stock market debut in Asia push markets to set records as tariff deal nears
Tiffany, Novartis, tariffs and Hong Kong push the stock exchanges
The grand relaunch of the Merger and Acquisition with the big deals of Tiffany and Novartis supports the rise of the markets - But the progress on tariffs and the Hong Kong vote also count
Novartis: maxi acquisition in US pharma
The Swiss giant announced the acquisition for 9,7 billion dollars of the American The Medicine Company, producer of an important drug against cholesterol
Hong Kong pushes stock markets upwards, Tiffany belongs to Lvmh
The victory of the Democrats in Hong Kong pushes the Asian markets upwards - Two big blows for Lvmh and Novartis: Arnault conquers Tiffany and the Swiss pharmaceutical company offers 7 billion for the American The Medicines
Pharmaceuticals, Novartis: maxi sale of 13 billion
The company sold its 36,5% stake in the Consumer Healthcare joint venture, which deals in non-prescription drugs, including popular and commonly used products, to GlaxoSmithKline
Novartis acquires AveXis for $8,7 billion
Announced the agreement for the acquisition and subsequent merger between the Swiss group and the American company specialized in genetic therapies for spinal muscular atrophy. Novartis expects to complete the transaction by mid-2018
Novartis, dividend rises to 2,8 francs: it is growing for the 21st consecutive year
In a note, the Basel group recalls that since the foundation of Novartis in 1996, the dividend has always increased and represents a payout of 67% on free cash flow.